depression
DEPRESSION

Depression is a mood disorder wherein the patient have a pervasive sad mood or loss of interest in most activities for at least 2 weeks.

It can cause significant distress & impairment. It is also a chronic, episodic and relapsing syndrome.

Treatment can either be by psychotherapy alone or pharmacotherapy alone or psychotherapy combined with pharmacological therapy.

  1. Duloxetine (Cymbalta): a new SNRI for depression. Med Lett Drugs Ther. 2004 Oct;46(1193):81-82. PMID: 15480298
  2. Ferguson JM. Depression: diagnosis and management for primary care physicians. J Clin Psychiatry. 2000 Oct;2(5):173-178
  3. Depont F, Rambelomanana S, Le Puil S, et al. Antidepressants: psychiatrists' opinions and clinical practice [abstract]. Acta Psychiatr Scan. 2003 Jul;108(1):24-31. PMID: 12807374
  4. Czeh B, Michaelis T, Watanabe T, et al. Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine. Proc Natl Acad Sci USA. 2001 Oct;98(22):12796-12801. PMID: 11675510
  5. Kent JM. SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet. 2000 Mar;355(9207):911-918. PMID: 10752718
  6. Kasper S, Olié JP. A meta-analysis of randomized controlled trials of tianeptine versus SSRI in the short-term treatment of depression [abstract]. Eur Psychiatry. 2002 Jul;17(Suppl 3):331-340. PMID: 15177089
  7. Whooley MA, Simon GE. Managing depression in medical outpatients. N Engl J Med. 2000 Dec;343(26):1942-4950. PMID: 11136266
  8. Waintraub L, Septein L, Azoulay P. Efficacy and safety of tianeptine in major depression: evidence from a 3-month controlled clinical trial versus paroxetine [abstract]. CNS Drugs. 2002;16(1):65-75. PMID: 11772119
  9. Sonawalla S, Chakraborty N, Parikh R. Treatment of major depression and anxiety with the selective serotonin re-uptake enhancer tianeptine in the outpatient psychiatric care setting of India. J Indian Med Assoc. 2003 Feb;101(2):116-117,124. PMID: 12841497
  10. Rush AJ. Mood disorders: treatment of depression. In: Sadock BJ, et al. Kaplan and Sadock's Comprehensive Textbook of Psychiatry. 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2009
  11. MedWormhttp://www.medworm.com/rss/index.php/Psychiatry/172/http://www.medworm.com/rss/medicalfeeds/specialities/Psychiatry.xml
  12. Ministry of Health Singapore. Depression. MOH (Singapore). http://www.moh.gov.sg. Mar 2004
  13. Institute for Clinical Systems Improvement (ICSI). Major depression in adults in primary care. http://bit.ly/Depr0512. May 2012.
  14. Institute for Clinical Systems Improvement (ICSI). Health care guideline: major depression in adults for mental health care providers. http://www.icsi.org. 2002
  15. National Institute of Mental Health. Depression. http://www.nimh.gov/publication/depression.cfm. 2002
  16. National Collaborating Centre for Mental Health. The treatment and management of depression in adults. http://www.nice.org.uk. Oct 2009. Accessed 14 Jan 2011.
  17. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder. 3rd ed. Psychiatryonline. http://psychiatryonline.org. Oct 2010.
  18. American Psychiatric Association. Depressive disorders. In: Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013:155-188.
  19. Bauer M, Pfennig A, Severus E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry. 2013 Jul;14(5):334-385. doi: 10.3109/15622975.2013.804195. PMID: 23879318
  20. Bauer M, Severus E, Kohler S, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. part 2: maintenance treatment of major depressive disorder-update 2015. World J Biol Psychiatry. 2015 Feb;16(2):76-95. doi: 10.3109/15622975.2014.1001786. PMID: 25677972
  21. Trangle M, Gursky J, Haight R, et al. Adult depression in primary care. Institute for Clinical Systems Improvement (ICSI). http://www.icsi.org. Mar 2016.
  22. Kennedy SH, Lam RW, McIntyre RS, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. pharmacological treatments. Can J Psychiatry. 2016 Sep;61(9):540-560. doi: 10.1177/0706743716659417. PMID: 27486148
  23. Parikh SV, Quilty LC, Ravitz P, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 2. psychological treatments. Can J Psychiatry. 2016 Sep;61(9):524-539. doi: 10.1177/0706743716659418. PMID: 27486150
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Psychiatry - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
The choice between nonvitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) for stroke prevention appears to be complex and largely heterogenous across different, countries, a new study has found.
Yesterday
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, 2 days ago
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, 2 days ago
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.